Abstract
Bezafibrate (Bf) is now clinically used as an effective antilipemic drug, especially against hypertriglyceridemia. Some of the literature states that Bf is also effective for lowering blood glucose concentrations, but few clinical data have yet been reported. We tried administeing Hf to 26 NIDDM patients moderately controlled with sulfonylurea or diet alone, and monitored serum lipid, glucose, glycohemoglobin (HbA1c) and insulin concentrations for six months. The results showed that serum triglyceride was significantly lower in 30% compared to before treatment, and that blood glucose had also been significantly reduced from 199±40 to 160±42 mg/dl in the fasting state. Glycohemoglobin levels were slightly elevated. This glucose-lowering effect of Hf is supposed to be due to inhibition of glucogenesis in the liver.
